Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Randomized, Double-blind, Multi-center Study to Investigate the Efficacy and Safety of PG-102(MG12) Compared With Placebo in Subjects With Obesity and in Subjects With Type 2 Diabetes Mellitus (T2DM)

NCT06712615 is registered in ClinicalTrials.gov with ProGen. Co., Ltd. as lead sponsor.

NCT NCT06712615
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06712615 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Randomized, Double-blind, Multi-center Study to Investigate the Efficacy and Safety of PG-102(MG12) Compared With Placebo in Subjects With Obesity and in Subjects With Type 2 Diabetes Mellitus (T2DM)
Lead sponsor
ProGen. Co., Ltd.
Phase
Phase 2
Overall status
Active, not recruiting
Start date
December 5, 2024
Completion date
October 30, 2025
Enrollment
144 (estimated)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

obesity type 2 diabetes mellitus, type 2 diabetes mellitus (t2dm)